Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Enhanced fluorescence imaging guided photodynamic therapy of sinoporphyrin sodium loaded graphene oxide" [Biomaterials 42 (2015) 16442].

Biomaterials·2026
Same author

[Expression of Concern] MicroRNA‑195 targets VEGFR2 and has a tumor suppressive role in ACHN cells via PI3K/Akt and Raf/MEK/ERK signaling pathways.

International journal of oncology·2025
Same author

Correction: DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin.

PloS one·2023
Same author

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis.

Frontiers in oncology·2022
Same author

Does laser treatment restore the bond strength of resin composites to recently bleached enamel? A systematic review and meta-analysis.

American journal of dentistry·2022
Same author

Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2022
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
07:53

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Published on: December 10, 2010

Phage display-derived peptides for osteosarcoma imaging.

Xilin Sun1, Gang Niu, Yongjun Yan

  • 1National Institute of Biomedical Imaging and Bioengineering, NIH, Bethesda, MD, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 24, 2010
PubMed
Summary
This summary is machine-generated.

Researchers identified a novel peptide, OSP-1, that specifically targets osteosarcoma cells. This peptide shows potential for developing new imaging agents for early osteosarcoma detection and treatment monitoring.

More Related Videos

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Related Experiment Videos

Last Updated: Jun 12, 2026

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
07:53

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Published on: December 10, 2010

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Osteosarcoma is the most common primary bone cancer in children.
  • Current survival rates for osteosarcoma have stagnated over the last two decades.
  • Improved diagnostic and therapeutic strategies are crucial for better patient outcomes.

Purpose of the Study:

  • To discover novel peptide sequences with specific binding affinity for osteosarcoma cells.
  • To develop new imaging agents for early osteosarcoma detection.
  • To assess tumor response to therapy using novel imaging probes.

Main Methods:

  • Phage display screening of a peptide library against osteosarcoma cells (143B) and control cells (293T).
  • Selection and characterization of the osteosarcoma-specific peptide, named OSP-1.
  • Conjugation of OSP-1 with fluorescent dyes and fluorine-18 for in vitro and in vivo imaging studies.

Main Results:

  • The peptide sequence ASGALSPSRLDT (OSP-1) was identified and showed high specificity for osteosarcoma cell lines.
  • OSP-1 demonstrated significant binding to osteosarcoma cells, with minimal binding to control cell lines.
  • (18)F-labeled OSP-1 exhibited enhanced accumulation in osteosarcoma tumors in vitro and in vivo compared to a scrambled peptide control.

Conclusions:

  • The OSP-1 peptide is highly specific for osteosarcoma.
  • OSP-1's binding may involve heparan sulfate proteoglycans.
  • Labeled OSP-1 holds promise as a new imaging probe for osteosarcoma detection and management.